GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2024
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that new scientific data and analyses on the gene therapy LUMEVOQ® will be presented at the 50th Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS) in Honolulu, Hawaii (March 2-7, 202